SiBone (NASDAQ:SIBN) Director John Gordon Freund Sells 12,132 Shares

Key Points

• SiBone Director John Gordon Freund sold 12,132 shares of the company's stock at an average price of $15.99, resulting in a total transaction value of approximately $193,990.68.
• After the sale, Freund's ownership in SiBone decreased by 11.68%, leaving him with 91,767 shares valued at around $1,467,354.33.
• SiBone's stock price recently fell to $15.40, and the company reported a negative earnings per share (EPS) of ($0.14), beating estimates slightly.

SiBone (NASDAQ:SIBN - Get Free Report) Director John Gordon Freund sold 12,132 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $15.99, for a total transaction of $193,990.68. Following the completion of the sale, the director directly owned 91,767 shares in the company, valued at approximately $1,467,354.33. This represents a 11.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

SiBone Price Performance

Shares of SiBone stock traded down $0.28 during trading hours on Monday, reaching $15.40. The stock had a trading volume of 266,453 shares, compared to its average volume of 432,345. The stock's 50 day moving average is $17.68 and its 200 day moving average is $16.62. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The firm has a market capitalization of $664.36 million, a PE ratio of -27.50 and a beta of 0.91.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The business had revenue of $48.63 million for the quarter, compared to the consensus estimate of $48.12 million. Equities analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Truist Financial upped their target price on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Wall Street Zen downgraded shares of SiBone from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the company an "overweight" rating in a research note on Monday.

Institutional Trading of SiBone

Several large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in SiBone by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock worth $328,000 after buying an additional 988 shares during the period. Invesco Ltd. lifted its holdings in SiBone by 8.9% during the 4th quarter. Invesco Ltd. now owns 17,203 shares of the company's stock worth $241,000 after buying an additional 1,413 shares during the last quarter. Rhumbline Advisers boosted its holdings in SiBone by 3.6% in the first quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after purchasing an additional 2,100 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in shares of SiBone during the 1st quarter worth approximately $34,000. Finally, Barclays PLC grew its position in shares of SiBone by 2.7% in the 4th quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after buying an additional 2,589 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company's stock.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.